MacroGenics | MGNX - Pre Tax Profit


MacroGenics reported $-14.93M in Pre-Tax Profit for its fiscal quarter ending in December of 2025.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Biogen USD 377.7M 433.7M Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Genmab DKK 55M 427M Dec/2025
Geron USD -3.64M 27.5M Mar/2026
Gilead Sciences USD 2.08B 1.56B Dec/2025
J&J USD 7.82B 2.86B Mar/2026
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
MacroGenics USD -14.93M 31.75M Dec/2025
Merck USD 3.42B 3.32B Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
Puma Biotechnology USD 20.61M 24.76M Sep/2024
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Xencor USD -128.64M 124.37M Mar/2026